目的:研究并评价磷脂复合物自微乳给药系统对芒果苷口服药动学性质的影响。方法:以大鼠为实验动物,分别灌胃给予芒果苷磷脂复合物自微乳(MPC-SMEDDS)、芒果苷磷脂复合物(MPC)及芒果苷原料(MGF),采用高效液相色谱法分别检测上述三组口服给药后不同时间的血药浓度,应用DAS 3.2.2软件计算药动学参数。结果:大鼠灌胃给药后,MPC-SMEDDS、MPC及MGF的t max分别为(0.358±0.069)、(1.400±0.548)、(3.000±1.414)h,C max分别为(3.343±1.776)、(0.718±0.296)、(0.432±0.184)mg/L,AUC0-∞分别为(6.779±2.896)、(3.178±0.749)、(2.529±0.628)mg/(L·h),与芒果苷原料相比,MPC-SMEDDS的最大血药浓度提高7.7倍(P<0.05),达峰时间则缩短了8倍(P<0.05),相对生物利用度为原料组的268.0%。结论:磷脂复合物自微乳给药系统对芒果苷口服药动学性质具有显著的改善作用。 Objective: To study and evaluate the effect of phospholipid self-microemulsion drug delivery system on the pharmacokinetics of mangiferin. Methods: The rats were used as experimental animals and were respectively administered with MPC-SMEDDS, MPC and MGF by gavage. The rats were killed by high performance liquid chromatography The plasma concentrations of the three groups at different times after oral administration were measured and the pharmacokinetic parameters were calculated using DAS 3.2.2 software. Results: The t max of MPC-SMEDDS, MPC and MGF were (0.358 ± 0.069), (1.400 ± 0.548) and (3.000 ± 1.414) h, respectively, and the C max were (3.343 ± 1.776) , (0.718 ± 0.296) and (0.432 ± 0.184) mg / L, respectively, and the AUC0-∞ values ​​were 6.779 ± 2.896, 3.178 ± 0.749 and 2.529 ± 0.628 mg / Compared with the MPC-SMEDDS group, MPC-SMEDDS increased the maximum plasma concentration by 7.7-fold (P <0.05) and peaked at 8-fold (P <0.05) with a relative bioavailability of 268.0% of the raw materials. Conclusion: The self-microemulsion delivery system of phospholipid complex has a significant improvement on oral pharmacokinetics of mangiferin.